Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
85.95 SEK | -0.23% | -1.43% | +4.41% |
May. 03 | Elekta Launches AI-Powered, Adaptive CT-Linac for Next Level Cancer Care | CI |
May. 03 | Elekta to Buy Philips Healthcare's Treatment Planning Patent Portfolio | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.41% | 3.12B | A | ||
+7.01% | 217B | B | ||
+11.01% | 190B | B- | ||
+19.20% | 143B | B- | ||
+30.79% | 111B | A- | ||
+1.10% | 64.59B | A- | ||
+13.95% | 52.36B | B+ | ||
-0.16% | 48.45B | B+ | ||
-6.20% | 38.03B | A | ||
+0.91% | 35.6B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EKTA B Stock
- Ratings Elekta AB